Stock Report

All about this stock under one free report Last Updated: 19-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Glaxosmithkline [Merged] Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: GSKCONS | BSE: 500676

₹10,732.60

up-down-arrow ₹496.30 (4.85%)

As on 15-Apr-2020IST

Market cap

info icon

₹45,225 Cr

Revenue (TTM)

info icon

₹4,984 Cr

P/E Ratio

info icon

39.1

P/B Ratio

info icon

10.2

Div. Yield

info icon

1 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -13.85 3.76 6.60 4.21 3.43
EBIT -32.64 13.56 17.81 15.75 13.18
Net Profit -19.89 25.14 27.18 21.59 15.66
EPS -19.89 25.14 27.18 21.59 15.66
Book Value -- -- 17.49 13.52 17.70
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-19Mar-18
EBIT-Margin info 20.3219.0723.9322.5918.97
Net Margin info 16.5615.6321.2918.8515.31
Return on equity info 23.1025.4028.0025.9321.19
Return on Capital info 35.5238.97--39.9232.54
Return on Assets info 9.9110.3819.7111.329.03
Debt to Equity (x) info ----0.000.000.00

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
--
39.92
32.54
34.10
42.98
Peer Median
--
15.93
15.22
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

28.00

Higher than Peers by 9.76

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
28.00
25.93
21.19
22.18
27.99
Peer Median
18.23
17.66
17.11
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

19.71

Higher than Peers by 6.92

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
19.71
11.32
9.03
9.38
11.15
Peer Median
12.79
6.89
5.73
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

23.93

Higher than Peers by 17.36

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
23.93
22.59
18.97
19.40
18.88
Peer Median
6.57
5.79
6.89
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

21.29

Higher than Peers by 16.01

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
21.29
18.85
15.31
15.52
15.57
Peer Median
5.29
4.08
3.73
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
--
21.82
17.47
16.29
16.32
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

6.60

Lower than Peers by 3.47

Year on year growth in net sales

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
6.60
10.78
8.15
-3.51
-3.98
Peer Median
10.07
8.84
8.37
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

17.81

Higher than Peers by 2.02

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
17.81
31.93
5.79
-0.84
16.88
Peer Median
15.79
0.84
36.52
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

27.18

Higher than Peers by 7.09

Year on year growth in profit after tax

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
27.18
40.38
6.61
-4.45
17.77
Peer Median
20.09
19.79
-0.86
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

27.18

Higher than Peers by 8.42

Year on year growth in earnings per share

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
27.18
40.38
6.61
-4.45
17.77
Peer Median
18.76
11.76
34.08
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
--
17.49
11.61
11.58
32.45
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
--
--
--
0.00
0.00
Peer Median
0.09
0.15
0.32
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

2.99

Higher than Peers by 1.11

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
2.99
2.47
2.62
2.59
2.58
Peer Median
1.88
1.91
1.77
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

2.75

Higher than Peers by 1.77

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
2.75
2.27
2.39
2.31
2.26
Peer Median
0.98
1.51
1.09
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

316.51

Higher than Peers by 300.68

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
316.51
1,943.07
530.19
364.69
464.16
Peer Median
15.83
14.63
4.93
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

8.01

Higher than Peers by 6.54

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
8.01
8.07
6.46
8.04
8.56
Peer Median
1.47
0.96
4.24
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.85

Lower than Peers by 1.05

Sales / Average Total Assets

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
0.85
0.55
0.56
0.63
0.74
Peer Median
1.90
1.61
1.52
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
--
25.36
25.01
27.84
26.69
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
--
33.39
36.30
38.05
37.10
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
--
109.00
113.91
109.20
96.61
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
--
-50.26
-52.61
-43.31
-32.82
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

39.13

Higher than Peers by 12.33

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
39.13
30.86
36.61
33.04
36.93
Peer Median
26.80
27.18
34.56
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

10.19

Higher than Peers by 6.36

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
10.19
7.41
7.36
6.95
9.07
Peer Median
3.83
5.27
6.06
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

0.98

Higher than Peers by 0.39

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
0.98
1.46
1.23
1.36
1.16
Peer Median
0.58
0.71
0.54
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

24.05

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
24.05
16.67
19.33
17.28
20.33
Peer Median
--
36.07
26.38
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

45,225

Higher than Peers by 39,934

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-19
Mar-18
Mar-17
Mar-16
Glaxosmithkline [Merged]
45,225
30,333
25,633
21,700
25,381
Peer Median
5,291
5,598
6,294
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...